Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · IEX Real-Time Price · USD
46.96
+0.57 (1.23%)
At close: Jul 19, 2024, 4:00 PM
46.97
+0.01 (0.02%)
Pre-market: Jul 22, 2024, 7:12 AM EDT
Soleno Therapeutics Employees
Soleno Therapeutics had 33 employees as of December 31, 2023. The number of employees increased by 1 or 3.13% compared to the previous year.
Employees
33
Change (1Y)
1
Growth (1Y)
3.13%
Revenue / Employee
n/a
Profits / Employee
-$1,576,667
Market Cap
1.71B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 33 | 1 | 3.13% |
Dec 31, 2022 | 32 | 1 | 3.23% |
Dec 31, 2021 | 31 | 0 | - |
Dec 31, 2020 | 31 | 6 | 24.00% |
Dec 31, 2019 | 25 | 2 | 8.70% |
Dec 31, 2018 | 23 | 5 | 27.78% |
Dec 31, 2017 | 18 | -11 | -37.93% |
Dec 31, 2016 | 29 | -13 | -30.95% |
Dec 31, 2015 | 42 | 23 | 121.05% |
Dec 31, 2014 | 19 | 6 | 46.15% |
Dec 31, 2013 | 13 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Evotec SE | 4,952 |
Galapagos NV | 1,123 |
Veracyte | 815 |
Supernus Pharmaceuticals | 652 |
Avadel Pharmaceuticals | 154 |
Kura Oncology | 142 |
Keros Therapeutics | 136 |
Neumora Therapeutics | 124 |
SLNO News
- 23 days ago - Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome - GlobeNewsWire
- 27 days ago - Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Soleno Therapeutics, Inc. (NASDAQ: SLNO) and Encourages Long-Term Investors to Contact the Firm - Accesswire
- 2 months ago - Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024 - GlobeNewsWire
- 2 months ago - Soleno Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Soleno Therapeutics Stands with the Prader-Willi Syndrome Community - GlobeNewsWire
- 2 months ago - Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock - GlobeNewsWire